Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Preveceutical Medical Inc PRVCF


Primary Symbol: C.PREV

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based... see more

Recent & Breaking News (CSE:PREV)

PreveCeutical Engages New to the Street for Production & Broadcasting Services

PR Newswire August 31, 2023

PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia

PR Newswire July 24, 2023

PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof

Newsfile June 28, 2023

PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update

Newsfile May 30, 2023

PreveCeutical Medical Launches Clinical Artificial Intelligence Division

Newsfile April 24, 2023

PreveCeutical Medical Announces Live Interactive Q&A Video Conference

Newsfile April 20, 2023

PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain

Newsfile April 4, 2023

PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee

Newsfile March 20, 2023

PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof

Newsfile March 6, 2023

Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors

Newsfile February 21, 2023

PreveCeutical (CSE:PREV) selects ICON PLC for painkiller clinical development

Caroline Egan  February 7, 2023

IIROC Trade Resumption - PREV

Canada NewsWire February 7, 2023

PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development

Newsfile February 7, 2023

IIROC Trading Halt - PREV

Canada NewsWire February 7, 2023

PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds

Newsfile January 25, 2023

PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds

Newsfile January 23, 2023

PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update

Newsfile January 17, 2023

PreveCeutical (CSE:PREV) signs licence option agreement with Endosane Pharmaceuticals

Azuka Onwuka January 12, 2023

PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals

Newsfile January 12, 2023

PreveCeutical signs (CSE:PREV) inter-company Sol-Gel licence agreement

Azuka Onwuka January 9, 2023